These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 29372582)

  • 1. Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial.
    Takeda K; Morita S
    Pharm Stat; 2018 Jul; 17(4):372-382. PubMed ID: 29372582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating Historical Data in Bayesian Phase I Trial Design: The Caucasian-to-Asian Toxicity Tolerability Problem.
    Takeda K; Morita S
    Ther Innov Regul Sci; 2015 Jan; 49(1):93-99. PubMed ID: 30222449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
    Takeda K; Taguri M; Morita S
    Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
    Morita S
    Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
    Hirakawa A
    Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.
    Riviere MK; Yuan Y; Jourdan JH; Dubois F; Zohar S
    Stat Methods Med Res; 2018 Feb; 27(2):466-479. PubMed ID: 26988926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology.
    Takeda K; Komatsu K; Morita S
    Pharm Stat; 2018 Nov; 17(6):725-733. PubMed ID: 30066356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bridging continual reassessment method for phase I clinical trials in different ethnic populations.
    Liu S; Pan H; Xia J; Huang Q; Yuan Y
    Stat Med; 2015 May; 34(10):1681-94. PubMed ID: 25626429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the relative conservativeness of Bayesian logistic regression method in oncology dose-finding studies.
    Yang CH; Cheng G; Lin R
    Pharm Stat; 2024; 23(4):585-594. PubMed ID: 38317370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
    Tighiouart M; Li Q; Rogatko A
    Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
    Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
    Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
    Tighiouart M; Cook-Wiens G; Rogatko A
    J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian three-parameter logistic model for early- and late-onset DLTs in oncology Phase I studies.
    Zheng W; Zhao Y; Lu Y; Miao H; Liu H
    J Biopharm Stat; 2016; 26(2):339-51. PubMed ID: 25629564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
    Chen X; Zhang J; Jiang Q; Yan F
    J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical aspects of the Bayesian approach to phase I cancer trials.
    Neuenschwander B; Branson M; Gsponer T
    Stat Med; 2008 Jun; 27(13):2420-39. PubMed ID: 18344187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.